# Rituximab and Interleukin-2 in Treating Patients With Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma

> **NCT00059904** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center**

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** aldesleukin
- **BIOLOGICAL:** rituximab

## Key facts

- **NCT ID:** NCT00059904
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-01
- **Primary completion:** —
- **Final completion:** 2004-06
- **Target enrollment:** — (—)
- **Last updated:** 2013-07-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00059904

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00059904, "Rituximab and Interleukin-2 in Treating Patients With Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00059904. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*